September 18, 2019
A UNC Healthcare announced on September 17, 2019: The National Institutes of Health have awarded two separate grants totaling $6.1 million to Mark Zylka, PhD, director of the UNC Neuroscience Center.at the UNC School of Medicine. One of these projects […]
Read more
May 30, 2019
Important work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is critically important to design […]
Read more
May 30, 2019
Your ASF donations hard at work at UNC and Erasmus Medical Center in the Netherlands. This pivotal study demonstrated that UBE3A is most critical in the developing brain and plays a less vital role later on in life. This is […]
Read more
May 30, 2019
Anxiety in Angelman Syndrome Important work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is […]
Read more
May 16, 2019
See the following announcement from May 16, 2019. Also, see a Q&A on this collaboration for more details. Dear Angelman Syndrome Community, We, Roche, Biogen and Ionis, are amongst several companies working towards finding potential treatments for Angelman Syndrome (AS). […]
Read more
November 22, 2018
Congratulations to Dr. Mark Zylka who has been recognized as a 2017 American Association for the Advancement of Science (AAAS) Fellow! The AAAS fellows date back to 1874 and have included such prestigious recipients as Thomas Edison and Margaret Mead. More recently, […]
Read more
November 22, 2018
World’s Largest Newborn Screening Study for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes Launches Nonprofits co-fund feasibility study to test screening tool for 75,000 newborns for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes AURORA, Ill., and WALNUT, Calif. (November 8, […]
Read more
October 25, 2018
Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting […]
Read more